Cardiff Oncology Analyst Price Targets - Benzinga

Cardiff Oncology Inc

CRDFNASDAQ

Trade with Public

Trade with Public

$1.09

0.010.93%

Last update: Sep 4, 9:09 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Cardiff Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cardiff Oncology (CRDF).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

2Buy

5Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$9Upside to Avg. PT+718.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	William Blair	Andy Hsieh	Downgrade	Outperform→Market Perform	—
Jun 3, 2026	Craig-Hallum	Albert Lowe	Downgrade	Buy→Hold	$10→$2
Jun 1, 2026	TD Cowen	Marc Frahm	Downgrade	Buy→Hold	—
Jun 1, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Feb 25, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$10→$6
Jan 28, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
Aug 6, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$18→$10
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$19
Jun 24, 2025	Jefferies	Maury Raycroft	Initiate	Hold	$4
May 9, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$17→$18
Feb 28, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$13→$17
Dec 13, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$7→$10
Nov 8, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$14→$13
Sep 6, 2024	Craig-Hallum	Albert Lowe	Initiate	Buy	$8
May 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$14
Mar 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$12→$14
Mar 1, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$5→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
William Blair Downgrades Cardiff Oncology to Market Perform

William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2

Craig-Hallum analyst Albert Lowe downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold and lowers the price target from $10 to $2.

Benzinga Newsdesk

PRO
TD Cowen Downgrades Cardiff Oncology to Hold

TD Cowen analyst Marc Frahm downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold.

Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Cardiff Oncology to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Neutral.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cardiff Oncology, Lowers Price Target to $6

Piper Sandler analyst Edward Tenthoff maintains Cardiff Oncology (NASDAQ:CRDF) with a Overweight and lowers the price target from $10 to $6.

Benzinga Newsdesk